Loading
PF-08046876 / Urothelial Carcinoma / Advanced/metastatic Solid Tumors · Phase 1 Trial
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 clinical trial registration for PF-08046876, an investigational antibody-drug conjugate in patients with advanced solid tumors. The study is recruiting and has not yet reported results; primary endpoints focus on safety, tolerability, and dose-escalation metrics. No clinical outcome data are available from this registry record.
Phase 1, Interventional, Sequential, Open label, Treatment purpose. Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamou…; age from 18 Years. Intervention: Part 1 Dose Escalation; Part 2 Dose Optimization; Part 2 Dose Expansion. n = 540. 31 sites across 6 countries.
This is a Phase 1 clinical trial registration for PF-08046876, an investigational antibody-drug conjugate in patients with advanced solid tumors. The study is recruiting and has not yet reported results; primary endpoints focus on safety, tolerability, and dose-escalation metrics. No clinical outcome data are available from this registry record.
Primary endpoints are safety and tolerability; efficacy outcomes are not specified in this registry entry.
No clinical impact can be assessed from this registry record, as the trial is ongoing and results have not been posted. Clinicians should monitor for future publication of safety and dose-escalation findings.
This is a Phase 1 trial registration with no results posted; it describes planned enrollment and safety endpoints in an early-stage study of an investigational antibody-drug conjugate.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed from this registry record, as the trial is ongoing and results have not been posted. Clinicians should monitor for future publication of safety and dose-escalation findings.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07090499). This is a study registration, not published results. Lead sponsor: Pfizer. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 540 participants (ESTIMATED). Conditions: Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer. Interventions: DRUG: PF-08046876. Primary outcome measures: Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation , Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first); Part 1: Number of Participants With Dose-limiting Toxicities (DLTs): Monotherapy , Baseline to end of DLT evaluation period; Part 1: Recommended Monotherapy Dose for Expansion , Baseline to 30 days post last study drug administration; Part 2: Recommended Phase 2 Dose , Baseline to 30 days post last study drug administration. Brief summary: The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.